ClinicalTrials.gg
Active, not recruitingNCT04216290Updated Nov 17, 2026Results posted

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

A Phase 2 interventional study of Biopsy of Bladder and Biospecimen Collection in Bladder Urothelial Carcinoma and Stage III Bladder Cancer AJCC v8, sponsored by National Cancer Institute (NCI). Active, not recruiting at 216 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment

How we know · 15 judgments · 4 readings being read again

Updated Nov 17, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 67 studies testing cisplatin in Urinary Bladder Neoplasms — 5 open to participants now, 11 under way, 1 of them phase 3. Cisplatin · Urinary Bladder Neoplasms.

Enrollment
56th of 66
11 · median 45
Started
2021
the only one that year
Phase 2
35 of 67
2 open now
Primary completion
2026-02
later than 1 of 10 live
Registered
58th of 67
by date

Among the 67 studies testing cisplatin in Urinary Bladder Neoplasms, this one is the 56th largest by enrollment of the 66 interventional ones that give a count, is the only one that started in 2021, is one of 35 in phase 2, reaches primary completion later than 1 of the 10 other live ones, and was the 58th registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

5 of the 67 studies testing cisplatin in Urinary Bladder Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing cisplatin in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

This phase II trial studies the benefit of adding an immunotherapy drug called MEDI4736 (durvalumab) to standard chemotherapy and radiation therapy in treating bladder cancer which has spread to the lymph nodes. Drugs used in standard chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with durvalumab may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving chemotherapy and radiation therapy with the addition of durvalumab may work better in helping tumors respond to treatment compared to chemotherapy and radiation therapy alone. Patients with limited regional lymph node involvement may benefit from attempt at bladder preservation, and use of immunotherapy and systemic chemotherapy.

Read the detailed description

PRIMARY OBJECTIVE:

I. To compare the clinical complete response rate (cCR) after chemoradiotherapy (chemoRT) with or without durvalumab in node-positive bladder cancer patients.

SECONDARY OBJECTIVES:

I. To compare the toxicity profile in both arms using the Common Terminology Criteria for Adverse Events (CTCAE).

II. To estimate the progression-free survival (PFS) in both arms. III. To estimate overall survival (OS) post randomization in both arms. IV. To estimate the bladder intact event free survival (BIEFS) in both arms. V. To estimate the metastasis free survival (MFS) in both arms. VI. To estimate bladder cancer specific survival in both arms. VII. To estimate the complete clinical response duration in both arms. VIII. To estimate salvage cystectomy rates in both arms.

EXPLORATORY OBJECTIVE:

I. Planned subgroup analyses for clinical outcome (clinical complete response [CR] rate post chemoRT +/- durvalumab, MFS, OS, PFS) based on stratification factors.

TRANSLATIONAL OBJECTIVE:

I. To collect and bank tumor tissue and blood specimens at pre-and post-treatment with chemoRT +/- durvalumab to determine predictive or prognostic markers.

OUTLINE:

STEP 1 - Randomization: Patients are randomized to 1 of 2 arms.

ARM C: Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients receive durvalumab intravenously (IV) over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes twice a week (BIW) for 6 weeks; or cisplatin IV over 30-60 minutes once a week (QW) for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV continuous infusion on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as computed tomography (CT) or magnetic resonance imaging (MRI) throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.

ARM D: Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes BIW for 6 weeks; or cisplatin IV over 30-60 minutes QW for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV continuous infusion on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.

STEP 2 - Registration: Patients are assigned to 1 of 2 arms.

ARM E: Patients previously randomized to Arm C (chemoradiation and durvalumab) who achieve clinical CR or clinical benefit receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.

ARM F: Patients previously randomized to Arm D (chemoradiation) who achieve clinical CR or clinical benefit undergo observation. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.

After completion of study treatment, patients are followed up every 12 weeks for 1 year, every 6 months for year 2, and then annually for years 3-4.

03

Conditions studied

  • Bladder Urothelial Carcinoma
  • Stage III Bladder Cancer AJCC v8

Keywords

  • Bladder Cancer
  • Chemoradiation
  • Durvalumab
04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • STEP 1 (RANDOMIZATION) ELIGIBILITY CRITERIA:
  • Patient must be >= 18 years of age.
  • Patient must have an (ECOG) performance status of 0-2 at the time of step 1 randomization.
  • Patient must have proven pure or mixed urothelial cancer of the bladder.

    • NOTE: Small cell carcinoma is excluded, however other variant histologies are permitted provided a component of urothelial carcinoma is present.
  • Patient must have documented node-positive and non- disease (any T, any N, M0).

Node positivity must have been defined prior to receiving any systemic chemotherapy or induction chemotherapy. Node positivity can fall into either of the following categories and will be defined by imaging and/or :

  • A lymph node >= 1.0 cm in short axis on imaging (i.e., CT or MRI or positron emission tomography [PET]/CT).
  • A lymph node that is \< 1 cm on imaging with either a biopsy confirming involvement with cancer or high suspicion of cancer.

    • For patients who have received induction chemotherapy (any type of systemic chemotherapy) for node positive bladder cancer prior to enrollment, there must be no signs of disease progression (CR/partial response [PR] or stable disease [SD]) based on restaging imaging and cystoscopy, which consists of:
  • CT chest, abdomen, and pelvis obtained after completion of induction chemotherapy and within 8 weeks prior to step 1 randomization.

    ** NOTE: MRI can be used instead of CT per treating physician discretion.

  • Cystoscopic evaluation and attempt to perform maximal transurethral resection of bladder tumor (TURBT) performed by the participating urologist after completion of induction chemotherapy and within 12 weeks prior to step 1 randomization. If maximal TURBT is not possible for medical reasons, the enrollment must be discussed and approved with the study chair. Documentation of correspondences with the study chair must be kept on file.
  • Patients who achieve CR upon cystoscopy per urologist with no visible tumor (i.e., no need for additional TURBT), are allowed to proceed in the study as adequate resection with no residual disease in bladder.

    • For patients who have did not receive induction chemotherapy (any type of systemic chemotherapy) for node positive bladder cancer prior to enrollment, the following must be obtained:
  • CT chest, abdomen, and pelvis completed within 8 weeks prior to step 1 randomization.

    ** NOTE: MRI can be used instead of CT per treating physician discretion.

  • Cystoscopic evaluation and attempt to perform maximal TURBT performed by the participating

urologist within 12 weeks prior to step 1 randomization. If maximal TURBT is not possible for medical reasons, the enrollment must be discussed and approved with the study chair.

Documentation of correspondences with the study chair must be kept on file.

  • For patients who may need repeat TURBT if their old TURBT has fallen out of window: If urologist determine no visible tumor (i.e., no need for additional resection) upon cystoscopy, they are allowed to proceed in the study as complete resection. • Patient must not have received any previous radiation therapy to the pelvic area.

    • Patient must agree to undergo CT simulation and treatment planning. If this is the first case registered at the site, then a pre-treatment radiation therapy (RT) review will be required and will take up to 3 business days. The patient cannot start radiation treatment prior to successful completion of this pre-treatment review. Therefore, careful planning is necessary to meet the deadline of starting radiation within 20 business days of step 1 randomization.
    • Patient must not have presence of concomitant active upper tract tumors or urethra tumors.

History of previously adequately treated non-muscle invasive bladder cancer (NMIBC) are eligible. Previously treated urothelial cancer or histological variant at any site outside of the urinary bladder are allowed, provided they have been Ta/T1/carcinoma in situ (CIS) and post treatment follow up imaging and endoscopic evaluation shows no evidence of disease.

  • Patients with previous exposure to for non-muscle invasive disease are eligible. If given for NMIBC, the last dose must have been completed > 12 months prior to step 1 randomization.
  • Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.

All patients of must have a blood test or urine study within 14 days prior to step 1 randomization to rule out pregnancy. A patient of childbearing potential is defined as any patient, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).

  • Patients must not expect to conceive or father children by using accepted and effected method(s) of or by abstaining from sexual intercourse from the time of step 1 randomization for the duration of their participation in the study and continue for at least 3 months after the last dose of protocol treatment.
  • Leukocytes >= 3,000/mcL (obtained \< 14 days prior to step 1 randomization).
  • (ANC) >= 1,500/mcL (obtained \< 14 days prior to step 1 randomization).
  • >= 9 g/dL (obtained \< 14 days prior to step 1 randomization).
  • >= 100,000/mcL (obtained \< 14 days prior to step 1 randomization).
  • Total \<= 1.5 x institutional (ULN) (obtained \< 14 days prior to step 1 randomization).
  • (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) \<= 2.5 x institutional ULN (obtained \< 14 days prior to step 1 randomization).
  • Adequate renal function as evidenced by calculated (Cockcroft's formula) or 24 hours actual creatinine clearance >= 30mL/min. The creatinine used to calculate the clearance result must have been obtained within 14 days prior to step 1 randomization. Actual body weight, not ideal body weight, must be used in the calculation.
  • Patients with (HIV) on effective anti-retroviral therapy with undetectable viral load within 6 months of step 1 randomization are eligible for this trial.
  • For patients with conditions, patient must not have history of prior documented autoimmune disease within 2 years prior to step 1 randomization. * NOTE: Patient with vitiligo, Grave's disease, eczema or psoriasis (not requiring systemic treatment within 2 years prior to step 1 randomization) are not excluded. Patients with history of completely resolved childhood asthma or atopy are not excluded. Patients with asthma not

requiring more than 10 mg/d or equivalent of prednisone are not excluded. Patients with well- controlled hypothyroidism on thyroxine replacement will be eligible as well. Patients with known history of hypoadrenalism on maintenance will be eligible. Patients with type I diabetes mellitus will be eligible, provided their disease is well controlled. History of autoimmune related alopecia is also not an exclusion criteria.

  • Patient with active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis) are not eligible.
  • Patient with a history of and/or confirmed pneumonitis are not eligible.
  • Patient with a history of primary immunodeficiency are not eligible.
  • Patient with history of allogeneic organ transplant are not eligible. • Patient must not have an active infection, including:
  • Tuberculosis (based on clinical evaluation that includes clinical history, physical examination, and radiographic findings, and tuberculosis testing in line with local practice).
  • (known positive hepatitis B virus [HBV] surface antigen [HBsAg] result). Past or resolved HBV infection (defined as the presence of hepatitis b core antibody [anti-HBc] and absence of HBsAg) are eligible.
  • . Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction test is negative for HCV ribonucleic acid (RNA).

    • Patient must not have liver disease that precludes patient from treatment regimens prescribed on the study (including, but not limited to, active viral, alcoholic or other autoimmune hepatitis, cirrhosis or inherited liver disease).
    • Patients with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial. Site is encouraged to discuss with the study chair if needed prior to enrollment.
    • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the Functional Classification. To be eligible for this trial, patients should be class IIB or better.
    • Patient must not have received within 30 days prior to the first dose of durvalumab
  • NOTE: Patient, if enrolled, must not receive live vaccine whilst receiving durvalumab and up to 30 days after the last dose of durvalumab.
  • NOTE: Patient is permitted to receive inactivated vaccines and any non-live vaccines including those for the seasonal influenza and coronavirus disease 2019 (COVID-19) (Note: intranasal influenza vaccines, such as Flu-Mist (registered trademark) are live attenuated vaccines and are not allowed). If possible, it is recommended to separate study drug administration from vaccine administration by about a week (primarily in order to minimize an overlap of adverse events).

    • Patient must not have current or prior use of medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:
  • Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection).
  • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent.
  • Steroids as premedication for reactions (e.g., CT scan premedication).

    • Patient must not have any unresolved toxicity (National Cancer Institute [NCI] grade >=2) from previous anti-cancer therapy with the exception of alopecia, vitiligo, and the laboratory values.
  • NOTE: Patients with grade >= 2 neuropathy will be evaluated on a case-by-case basis after consultation with the study chair.
  • NOTE: Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the study chair.

Documentation of correspondences with the study chair must be kept on file.

  • STEP 2 (REGISTRACTION: ADJUVANT DURVALUMAB VERSUS [VS] OBSERVATION)

ELIGIBILITY CRITERIA:

  • Patient must have evaluation to determine clinical outcome post step 1 treatment (chemoRT+/-durvalumab) with imaging (CT chest, abdomen, and pelvis) (preferably contrast with urogram, if not ) and cystoscopy with biopsy confirmation to ensure no progression and absence of >= T2 disease in the bladder. Patient should be registered to step 2 within 28 days from the determination of primary response to step 1 treatment. However, for patients previously on Arm C, an additional 4 week delay to step 2 registration is allowed.
  • Patient on the chemoRT+ durvalumab (Arm C) must meet the following:

    • Patient must have achieved either complete clinical response OR have demonstrated clinical benefit prior to continuing onto adjuvant durvalumab.
    • Patients who are to go on the adjuvant durvalumab (Arm E) must have recovered to at least grade 2 or less immune related adverse event (AE) prior to starting treatment except for immune related alopecia, clinically asymptomatic endocrinopathies. For patients who may have gotten immune related AEs during chemoRT+ durvalumab (Arm C), step 2 registration could be delayed up to additional 4 weeks to ensure recovery to at least grade 2 or lower prior to starting therapy. However patients with durvalumab related AEs that require permanent discontinuation of durvalumab will not continue on the adjuvant treatment regardless of the response.
    • Patient must not have experienced immune related neurological disorder described as Guillain- Barré syndrome, myasthenic syndrome or myasthenia gravis, or meningoencephalitis during chemoRT+ durvalumab treatment.
    • Patient must not have experienced immune related myocarditis or immune related pericarditis during chemoRT+ durvalumab treatment.
    • ANC >= 1,000 mcL (must be obtained \< 28 days prior to step 2 registration).
    • Hemoglobin >= 8g/dL (must be obtained \< 28 days prior to step 2 registration).
    • Platelets >= 70,000 mcL (must be obtained \< 28 days prior to step 2 registration).

      • NOTE: If recovery is not achieved, blood counts could be repeated weekly and step 2 registration could be delayed up to additional 4 weeks.
  • Patient on the chemoRT arm (Arm D) must have achieved either complete clinical response OR have demonstrated clinical benefit prior to be placed on the observation alone arm (Arm F).
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Step 1, Arm C (durvalumab, radiation therapy, chemotherapy)

    Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes BIW for 6 weeks; or cisplatin IV over 30-60 minutes QW for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV continuous infusion on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.

    Procedure: Biopsy of Bladder · Procedure: Biospecimen Collection · Drug: Cisplatin · Procedure: Computed Tomography · Procedure: Cystoscopy · Biological: Durvalumab · Drug: Fluorouracil · Drug: Gemcitabine Hydrochloride · Procedure: Magnetic Resonance Imaging · Drug: Mitomycin · Radiation: Radiation Therapy

  • Active comparator
    Step 1, Arm D (radiation therapy, chemotherapy)

    Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes BIW for 6 weeks; or cisplatin IV over 30-60 minutes QW for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV continuous infusion on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.

    Procedure: Biopsy of Bladder · Procedure: Biospecimen Collection · Drug: Cisplatin · Procedure: Computed Tomography · Procedure: Cystoscopy · Drug: Fluorouracil · Drug: Gemcitabine Hydrochloride · Procedure: Magnetic Resonance Imaging · Drug: Mitomycin · Radiation: Radiation Therapy

  • Experimental
    Step 2, Arm E (durvalumab)

    Patients previously randomized to Arm C (chemoradiation and durvalumab) who achieve clinical CR or clinical benefit receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.

    Procedure: Biopsy of Bladder · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: Cystoscopy · Biological: Durvalumab · Procedure: Magnetic Resonance Imaging

  • Active comparator
    Step 2, Arm F (observation)

    Patients previously randomized to Arm D (chemoradiation) who achieve clinical CR or clinical benefit undergo observation undergo observation. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.

    Procedure: Biopsy of Bladder · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: Cystoscopy · Procedure: Magnetic Resonance Imaging · Other: Patient Observation

Interventions

  • ProcedureBiopsy of Bladder

    Undergo bladder biopsy

    Also known as: Bladder Biopsy

  • ProcedureBiospecimen Collection

    Undergo tumor tissue and blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • Given IV

    Also known as: Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin

  • ProcedureComputed Tomography

    Undergo CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • ProcedureCystoscopy

    Undergo cystoscopy

    Also known as: CS

  • BiologicalDurvalumab

    Given IV

    Also known as: Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736

  • Given IV

    Also known as: 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757

  • DrugGemcitabineBeing read again: the record changed after it was read.Studies of GemcitabineGemcitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • Given IV

    Also known as: Ametycine, Jelmyto, MITO, Mito-C, Mito-Medac, Mitocin, Mitocin-C, Mitolem, Mitomycin C, Mitomycin pyelocalyceal, Mitomycin-C, Mitomycin-X, Mitomycine C, Mitosol, Mitozytrex, Mutamycin, Mutamycine, NCI-C04706

  • OtherPatient Observation

    Undergo observation

    Also known as: Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting

  • RadiationRadiation Therapy

    Undergo radiation therapy

    Also known as: Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation

06

What researchers measure

Primary outcomes

  1. Clinical Complete Response

    Clinical complete response is defined as complete response in bladder and nodes with no distant metastases.

    Time frame: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4

Secondary outcomes

  1. Treatment-related Grade 3 or Higher Adverse Event Rate

    Proportion of patients with grade 3 or higher adverse events that are definitely, probably or possibly related to protocol therapies per the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    Time frame: Assessed every 3 weeks while on treatment, up to 4 years

  2. Progression-free Survival (PFS)

    Progression-free survival is defined as the time from randomization to disease progression or death, whichever occurs first. Patients with evidence of progression in the bladder or lymph nodes that are unresectable, or with a presence of distant metastasis are considered as experiencing disease progression. For progression in bladder: cystoscopy will be performed and documentation of T2 disease is needed either by pathology or by treating urologist (this is to incorporate circumstances such - when T2 is suspected by urologist but adequate TURBT could not be done for concerns of perforating the bladder). Pathological confirmation is preferred. For response evaluation by imaging: at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4

  3. Duration of Complete Response

    Duration of complete response is defined as the time from documentation of complete response to disease progression, death or last disease assessment. Clinical complete response is defined as complete response in bladder and nodes with no distant metastases. For progression in bladder: cystoscopy will be performed and documentation of T2 disease is needed either by pathology or by treating urologist (this is to incorporate circumstances such - when T2 is suspected by urologist but adequate TURBT could not be done for concerns of perforating the bladder). Pathological confirmation is preferred. For progression evaluated by imaging: at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4

  4. 1-year Overall Survival (OS) Rate

    Overall survival is defined as the time from randomization to death or date last known alive. The method of Kaplan-Meier was used to estimate 1-year OS rate.

    Time frame: Assessed at baseline, every 12 weeks for 1 year

  5. Bladder Intact Event Free Survival (BIEFS)

    BIEFS is defined as time from randomization to presence of muscle invasive bladder cancer, clinical evidence of progression of nodal involvement or development of met disease, radical cystectomy, or death due to any cause.

    Time frame: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4

  6. Metastasis-free Survival (MFS)

    MFS is defined as time from randomization to first evidence of metastatic disease or death from any cause.

    Time frame: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4

  7. 1-year Bladder Cancer-specific Survival Rate

    Bladder cancer-specific survival is the time from randomization to death from bladder cancer. Deaths due to other causes will be considered competing events and patients known to be alive will be censored at the date of last contact. The method of Kaplan-Meier was used to estimate 1-year bladder cancer-specific survival rate.

    Time frame: Assessed at baseline, every 12 weeks for 1 year

  8. Salvage Cystectomy Rate

    Proportion of patients with salvage cystectomy performed

    Time frame: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4

Other outcomes

  1. Associations Between Clinical Outcomes and Stratification Factors

    Planned subgroup analyses for clinical outcome (Clinical CR rate post chemoRT+/- durvalumab, MFS, OS, PFS) based on stratification factors.

    Time frame: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4

  2. To Collect and Bank Tumor Tissue and Blood Specimens at Pre- and Post-treatment With chemoRT +/- Durvalumab to Determine Predictive or Prognostic Markers.

    To collect and bank tumor tissue and blood specimens at pre- and post-treatment with chemoRT +/- durvalumab to determine predictive or prognostic markers.

    Time frame: Assessed at baseline and 16 weeks

07

Results

Posted Nov 17, 2026

Participant flow

The study was activated on August 25, 2020 and the first patient was enrolled on March 17, 2021. Due to slow accrual, the study was closed on October 2, 2023.

Induction
Participant flow — Induction
MilestoneArm C (chemoRT+Durvalumab) Then Arm E (Adjuvant Durvalumab)Arm D (chemoRT) Then Arm F (Observation)Not Randomized
Started533
Completed530
Not completed003
Withdrew: Progressive disease001
Withdrew: Withdrawal by subject001
Withdrew: Had surgery and needed to recover001
Randomization (Step 1)
Participant flow — Randomization (Step 1)
MilestoneArm C (chemoRT+Durvalumab) Then Arm E (Adjuvant Durvalumab)Arm D (chemoRT) Then Arm F (Observation)Not Randomized
Started530
Completed520
Not completed010
Withdrew: Adverse event010
Adjuvant Treatment/Observation (Step 2)
Participant flow — Adjuvant Treatment/Observation (Step 2)
MilestoneArm C (chemoRT+Durvalumab) Then Arm E (Adjuvant Durvalumab)Arm D (chemoRT) Then Arm F (Observation)Not Randomized
Started520
Completed210
Not completed310
Withdrew: Physician decision100
Withdrew: Withdrawal by subject100
Withdrew: Progressive disease110

Outcome measures

PrimaryClinical Complete Response

Clinical complete response is defined as complete response in bladder and nodes with no distant metastases.

Time frame:
Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
Reported as:
Count of participants · Participants
Clinical Complete Response
ParticipantsStep 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy)Step 1, Arm D (Radiation Therapy, Chemotherapy)
Clinical Complete Response21
SecondaryTreatment-related Grade 3 or Higher Adverse Event Rate

Proportion of patients with grade 3 or higher adverse events that are definitely, probably or possibly related to protocol therapies per the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

Time frame:
Assessed every 3 weeks while on treatment, up to 4 years
Reported as:
Number · Proportion of participants
Treatment-related Grade 3 or Higher Adverse Event Rate
Proportion of participantsStep 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy)Step 1, Arm D (Radiation Therapy, Chemotherapy)
Treatment-related Grade 3 or Higher Adverse Event Rate0.8 (0.34 to 0.99)1.0 (0.37 to 1.0)
SecondaryProgression-free Survival (PFS)

Progression-free survival is defined as the time from randomization to disease progression or death, whichever occurs first. Patients with evidence of progression in the bladder or lymph nodes that are unresectable, or with a presence of distant metastasis are considered as experiencing disease progression. For progression in bladder: cystoscopy will be performed and documentation of T2 disease is needed either by pathology or by treating urologist (this is to incorporate circumstances such - when T2 is suspected by urologist but adequate TURBT could not be done for concerns of perforating the bladder). Pathological confirmation is preferred. For response evaluation by imaging: at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
Reported as:
Median · month
Progression-free Survival (PFS)
monthStep 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy)Step 1, Arm D (Radiation Therapy, Chemotherapy)
Progression-free Survival (PFS)23.2 (9.5 to NA)9.1 (3.5 to NA)
SecondaryDuration of Complete Response

Duration of complete response is defined as the time from documentation of complete response to disease progression, death or last disease assessment. Clinical complete response is defined as complete response in bladder and nodes with no distant metastases. For progression in bladder: cystoscopy will be performed and documentation of T2 disease is needed either by pathology or by treating urologist (this is to incorporate circumstances such - when T2 is suspected by urologist but adequate TURBT could not be done for concerns of perforating the bladder). Pathological confirmation is preferred. For progression evaluated by imaging: at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
Reported as:
Median · month
Duration of Complete Response
monthStep 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy)Step 1, Arm D (Radiation Therapy, Chemotherapy)
Duration of Complete Response5.4 (5.2 to 5.6)5.9 (5.9 to 5.9)
Secondary1-year Overall Survival (OS) Rate

Overall survival is defined as the time from randomization to death or date last known alive. The method of Kaplan-Meier was used to estimate 1-year OS rate.

Time frame:
Assessed at baseline, every 12 weeks for 1 year
Reported as:
Number · percentage of participants
1-year Overall Survival (OS) Rate
percentage of participantsStep 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy)Step 1, Arm D (Radiation Therapy, Chemotherapy)
1-year Overall Survival (OS) Rate66.7 (30 to 100)100 (100 to 100)
SecondaryBladder Intact Event Free Survival (BIEFS)

BIEFS is defined as time from randomization to presence of muscle invasive bladder cancer, clinical evidence of progression of nodal involvement or development of met disease, radical cystectomy, or death due to any cause.

Time frame:
Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
Reported as:
Median · month
Bladder Intact Event Free Survival (BIEFS)
monthStep 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy)Step 1, Arm D (Radiation Therapy, Chemotherapy)
Bladder Intact Event Free Survival (BIEFS)22.3 (9.5 to NA)9.1 (3.5 to NA)
SecondaryMetastasis-free Survival (MFS)

MFS is defined as time from randomization to first evidence of metastatic disease or death from any cause.

Time frame:
Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
Reported as:
Median · month
Metastasis-free Survival (MFS)
monthStep 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy)Step 1, Arm D (Radiation Therapy, Chemotherapy)
Metastasis-free Survival (MFS)22.3 (9.5 to NA)9.1 (3.5 to NA)
Secondary1-year Bladder Cancer-specific Survival Rate

Bladder cancer-specific survival is the time from randomization to death from bladder cancer. Deaths due to other causes will be considered competing events and patients known to be alive will be censored at the date of last contact. The method of Kaplan-Meier was used to estimate 1-year bladder cancer-specific survival rate.

Time frame:
Assessed at baseline, every 12 weeks for 1 year
Reported as:
Number · percentage of participants
1-year Bladder Cancer-specific Survival Rate
percentage of participantsStep 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy)Step 1, Arm D (Radiation Therapy, Chemotherapy)
1-year Bladder Cancer-specific Survival Rate66.7 (30 to 100)100 (100 to 100)
SecondarySalvage Cystectomy Rate

Proportion of patients with salvage cystectomy performed

Time frame:
Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
Reported as:
Count of participants · Participants
Salvage Cystectomy Rate
ParticipantsStep 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy)Step 1, Arm D (Radiation Therapy, Chemotherapy)
Salvage Cystectomy Rate00
Other pre-specifiedAssociations Between Clinical Outcomes and Stratification Factors

Planned subgroup analyses for clinical outcome (Clinical CR rate post chemoRT+/- durvalumab, MFS, OS, PFS) based on stratification factors.

Time frame:
Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4

Results for this outcome have not been posted.

Other pre-specifiedTo Collect and Bank Tumor Tissue and Blood Specimens at Pre- and Post-treatment With chemoRT +/- Durvalumab to Determine Predictive or Prognostic Markers.

To collect and bank tumor tissue and blood specimens at pre- and post-treatment with chemoRT +/- durvalumab to determine predictive or prognostic markers.

Time frame:
Assessed at baseline and 16 weeks

Results for this outcome have not been posted.

Adverse events

Collected over Assessed every 3 weeks while on treatment and for 30 days after the end of treatment, up to 4 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Induction1/4 (25%)3/4 (75%)4/4 (100%)
Arm C (ChemoRT + Durvalumab)0/5 (0%)1/5 (20%)5/5 (100%)
Arm D (ChemoRT)0/3 (0%)1/3 (33.3%)3/3 (100%)
Arm E (Adjuvant Durvalumab)1/5 (20%)1/5 (20%)5/5 (100%)
Arm F (Observation)0/2 (0%)0/2 (0%)2/2 (100%)
Most frequent serious events
Most frequent serious events
EventInductionArm C (ChemoRT + Durvalumab)Arm D (ChemoRT)Arm E (Adjuvant Durvalumab)Arm F (Observation)
AnemiaBlood and lymphatic system disorders0/41/51/30/50/2
SepsisInfections and infestations0/40/51/31/50/2
HypoxiaRespiratory, thoracic and mediastinal disorders0/40/51/30/50/2
Wound dehiscenceInjury, poisoning and procedural complications1/40/50/30/50/2
HypoalbuminemiaMetabolism and nutrition disorders1/40/50/30/50/2
Adult respiratory distress syndromeRespiratory, thoracic and mediastinal disorders1/40/50/30/50/2
Acute kidney injuryRenal and urinary disorders1/41/50/30/50/2
COVIDRespiratory, thoracic and mediastinal disorders1/40/50/30/50/2
Urinary tract infectionInfections and infestations0/41/50/31/50/2
Most frequent other events
Showing 10 of 66
Most frequent other events
EventInductionArm C (ChemoRT + Durvalumab)Arm D (ChemoRT)Arm E (Adjuvant Durvalumab)Arm F (Observation)
AnemiaBlood and lymphatic system disorders3/45/53/30/50/2
Lymphocyte count decreasedInvestigations0/44/53/30/50/2
FatigueGeneral disorders1/44/52/30/50/2
DiarrheaGastrointestinal disorders0/44/52/30/50/2
HyponatremiaMetabolism and nutrition disorders2/44/52/31/50/2
NauseaGastrointestinal disorders2/43/52/30/50/2
Platelet count decreasedInvestigations0/42/52/30/50/2
White blood cell decreasedInvestigations1/40/52/30/50/2
HyperglycemiaMetabolism and nutrition disorders1/40/52/32/50/2
HypoalbuminemiaMetabolism and nutrition disorders1/41/52/30/50/2

Baseline characteristics

All patients enrolled are included in this analysis.

Age, Continuous
Age, Continuous(years)Step 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy)Step 1, Arm D (Radiation Therapy, Chemotherapy)Not RandomizedTotal
Median64.3 (63.2 to 84)69.6 (69.2 to 74.6)80.2 (79.0 to 87.6)73.9 (63.2 to 87.6)
Sex: Female, Male
Sex: Female, Male(Participants)Step 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy)Step 1, Arm D (Radiation Therapy, Chemotherapy)Not RandomizedTotal
Female1225
Male4116
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Step 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy)Step 1, Arm D (Radiation Therapy, Chemotherapy)Not RandomizedTotal
Hispanic or Latino0000
Not Hispanic or Latino53311
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Step 1, Arm C (Durvalumab, Radiation Therapy, Chemotherapy)Step 1, Arm D (Radiation Therapy, Chemotherapy)Not RandomizedTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White53311
More than one race0000
Unknown or Not Reported0000
08

Study locations

216 sites

Showing the first 100 of 216 sites. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Feb 2026, 58 months.

Results were first posted in Nov 2026, 9 months after primary completion.

Of 154 non-industry phase 2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 94. This study's 58 months is close to that.

Counting every sponsor, half of 193 studies reached it within 52 months; a quarter within 36 and three quarters within 91.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2019
First posted
Jan 2, 2020
StartActual
Mar 17, 2021
Primary completionActual
Feb 4, 2026
CompletionEst.
May 19, 2027
Results first posted
Nov 17, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 17, 2026
Eligibility
14 criteria edited, 4 added, 3 removed
What changed in the criteria
  • EditedPatient must have documented node-positive and non-metastatic disease (any T, any N, M0). Node positivity must have been defined prior to receiving any systemic chemotherapy or induction chemotherapy.
  • EditedNode positivity must have been defined prior to receiving any systemic chemotherapy or induction chemotherapy. Node positivity can fall into either of the following categories and will be defined by imaging and/or biopsy:
  • AddedCystoscopic evaluation and attempt to perform maximal TURBT performed by the participating
  • EditedCystoscopic evaluation and attempt to perform maximal TURBT performed by the participating urologist within 12 weeks prior to step 1 randomization. If maximal TURBT is not possible for medical reasons, the enrollment must be discussed and approved with the study chair. Documentation of correspondences with the study chair must be kept on file.
  • AddedDocumentation of correspondences with the study chair must be kept on file.
  • EditedFor patients who may need repeat TURBT if their old TURBT has fallen out of window: If urologist determine no visible tumor (i.e., no need for additional resection) upon cystoscopy, they are allowed to proceed in the study as complete resection. • Patient must not have received any previous radiation therapy to the pelvic area.
  • RemovedPatient must not have received any previous radiation therapy to the pelvic area.
  • AddedPatient must not have presence of concomitant active upper tract tumors or urethra tumors.
  • EditedPatient must not have presence of concomitant active upper tract tumors or urethra tumors. History of previously adequately treated non-muscle invasive bladder cancer (NMIBC) are eligible. Previously treated urothelial cancer or histological variant at any site outside of the urinary bladder are allowed, provided they have been Ta/T1/carcinoma in situ (CIS) and post treatment follow up imaging and endoscopic evaluation shows no evidence of disease.
  • RemovedAll patients of childbearing potential must have a blood test or urine study within 14 days prior to step 1 randomization to rule out pregnancy.
  • EditedAll patients of childbearing potential must have a blood test or urine study within 14 days prior to step 1 randomization to rule out pregnancy. A patient of childbearing potential is defined as any patient, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
  • EditedTotal bilirubin <=< 1.5 x institutional upper limit of normal (ULN) (obtained < 14 days prior to step 1 randomization).
  • EditedAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) <=< 2.5 x institutional ULN (obtained < 14 days prior to step 1 randomization).
  • EditedFor patients with autoimmune conditions, patient must not have history of prior documented autoimmune disease within 2 years prior to step 1 randomization. * NOTE: Patient with vitiligo, Grave's disease, eczema or psoriasis (not requiring systemic treatment within 2 years prior to step 1 randomization) are not excluded. Patients with history of completely resolved childhood asthma or atopy are not excluded. Patients with asthma not
  • EditedNOTE: Patient with vitiligo, Grave's disease, eczema or psoriasis (not requiring systemic treatment within 2 years prior to step 1 randomization) are not excluded. Patients with history of completely resolved childhood asthma or atopy are not excluded. Patients with asthma not requiring more than 10 mg/d or equivalent of prednisone are not excluded. Patients with well- controlled hypothyroidism on thyroxine replacement will be eligible as well. Patients with known history of hypoadrenalism on maintenance steroids will be eligible. Patients with type I diabetes mellitus will be eligible, provided their disease is well controlled. History of autoimmune related alopecia is also not an exclusion criteria.
  • EditedPatient with history of allogeneic organ transplant are not eligible. • Patient must not have an active infection, including:
  • RemovedPatient must not have an active infection, including:
  • EditedNOTE: Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the study chair. Documentation of correspondences with the study chair must be kept on file.
  • AddedDocumentation of correspondences with the study chair must be kept on file.
  • EditedSTEP 2 (REGISTRACTION: ADJUVANT DURVALUMAB VERSUS [VS] OBSERVATION) ELIGIBILITY CRITERIA:
  • EditedInclusion CriteriaELIGIBILITY CRITERIA:
Nov 17, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedClinical complete response (CR)Complete ResponseTime frame: Up to 4 years → Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
Nov 17, 2026
Secondary outcomes
6 edited, 4 added, 2 removed
What changed in the outcomes
  • EditedMetastasisProgression-free survivalSurvival (PFS)Time frame: From randomization to first evidence of metastatic disease or death from any cause, assessed up to 4 years → Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
  • EditedBladder-intact event-free survival Intact Event Free Survival (BI-EFSBIEFS)Time frame: From randomization to the first BI-EFS event, assessed up to 4 years → Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
  • Edited1-year Bladder cancer Cancer-specific survivalSurvival RateTime frame: From randomization to death from bladder cancer, assessed up to 4 years → Assessed at baseline, every 12 weeks for 1 year
  • EditedProgressionMetastasis-free survivalSurvival (MFS)Time frame: From randomization to first of local progression, nodal or distant metastasis, or death from any cause, assessed up to 4 years → Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
  • EditedDuration of Complete response durationResponseTime frame: From the date of the biopsy documenting the complete response to the time of muscle invasive recurrence, local progression, evidence of metastatic disease or death due to any cause, assessed up to 4 years → Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
  • EditedSalvage cystectomy rateCystectomy RateTime frame: Up to 4 years → Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
  • AddedTreatment-related Grade 3 or Higher Adverse Event RateTime frame: Assessed every 3 weeks while on treatment, up to 4 years
  • Added1-year Overall Survival (OS) RateTime frame: Assessed at baseline, every 12 weeks for 1 year
  • RemovedOverall survivalTime frame: From randomization to death from any cause, assessed up to 4 years
  • RemovedIncidence of adverse eventsTime frame: Up to 4 years
  • Addedother outcomeAssociations Between Clinical Outcomes and Stratification FactorsTime frame: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
  • Addedother outcomeTo Collect and Bank Tumor Tissue and Blood Specimens at Pre- and Post-treatment With chemoRT +/- Durvalumab to Determine Predictive or Prognostic Markers.Time frame: Assessed at baseline and 16 weeks
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Results posted
    Eligibility 14 criteria edited, 4 added, 3 removed
    What changed in the criteria
    • EditedPatient must have documented node-positive and non-metastatic disease (any T, any N, M0). Node positivity must have been defined prior to receiving any systemic chemotherapy or induction chemotherapy.
    • EditedNode positivity must have been defined prior to receiving any systemic chemotherapy or induction chemotherapy. Node positivity can fall into either of the following categories and will be defined by imaging and/or biopsy:
    • AddedCystoscopic evaluation and attempt to perform maximal TURBT performed by the participating
    • EditedCystoscopic evaluation and attempt to perform maximal TURBT performed by the participating urologist within 12 weeks prior to step 1 randomization. If maximal TURBT is not possible for medical reasons, the enrollment must be discussed and approved with the study chair. Documentation of correspondences with the study chair must be kept on file.
    • AddedDocumentation of correspondences with the study chair must be kept on file.
    • EditedFor patients who may need repeat TURBT if their old TURBT has fallen out of window: If urologist determine no visible tumor (i.e., no need for additional resection) upon cystoscopy, they are allowed to proceed in the study as complete resection. • Patient must not have received any previous radiation therapy to the pelvic area.
    • RemovedPatient must not have received any previous radiation therapy to the pelvic area.
    • AddedPatient must not have presence of concomitant active upper tract tumors or urethra tumors.
    • EditedPatient must not have presence of concomitant active upper tract tumors or urethra tumors. History of previously adequately treated non-muscle invasive bladder cancer (NMIBC) are eligible. Previously treated urothelial cancer or histological variant at any site outside of the urinary bladder are allowed, provided they have been Ta/T1/carcinoma in situ (CIS) and post treatment follow up imaging and endoscopic evaluation shows no evidence of disease.
    • RemovedAll patients of childbearing potential must have a blood test or urine study within 14 days prior to step 1 randomization to rule out pregnancy.
    • EditedAll patients of childbearing potential must have a blood test or urine study within 14 days prior to step 1 randomization to rule out pregnancy. A patient of childbearing potential is defined as any patient, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
    • EditedTotal bilirubin <=< 1.5 x institutional upper limit of normal (ULN) (obtained < 14 days prior to step 1 randomization).
    • EditedAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) <=< 2.5 x institutional ULN (obtained < 14 days prior to step 1 randomization).
    • EditedFor patients with autoimmune conditions, patient must not have history of prior documented autoimmune disease within 2 years prior to step 1 randomization. * NOTE: Patient with vitiligo, Grave's disease, eczema or psoriasis (not requiring systemic treatment within 2 years prior to step 1 randomization) are not excluded. Patients with history of completely resolved childhood asthma or atopy are not excluded. Patients with asthma not
    • EditedNOTE: Patient with vitiligo, Grave's disease, eczema or psoriasis (not requiring systemic treatment within 2 years prior to step 1 randomization) are not excluded. Patients with history of completely resolved childhood asthma or atopy are not excluded. Patients with asthma not requiring more than 10 mg/d or equivalent of prednisone are not excluded. Patients with well- controlled hypothyroidism on thyroxine replacement will be eligible as well. Patients with known history of hypoadrenalism on maintenance steroids will be eligible. Patients with type I diabetes mellitus will be eligible, provided their disease is well controlled. History of autoimmune related alopecia is also not an exclusion criteria.
    • EditedPatient with history of allogeneic organ transplant are not eligible. • Patient must not have an active infection, including:
    • RemovedPatient must not have an active infection, including:
    • EditedNOTE: Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the study chair. Documentation of correspondences with the study chair must be kept on file.
    • AddedDocumentation of correspondences with the study chair must be kept on file.
    • EditedSTEP 2 (REGISTRACTION: ADJUVANT DURVALUMAB VERSUS [VS] OBSERVATION) ELIGIBILITY CRITERIA:
    • EditedInclusion CriteriaELIGIBILITY CRITERIA:
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedClinical complete response (CR)Complete ResponseTime frame: Up to 4 years → Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
    Secondary outcomes 6 edited, 4 added, 2 removed
    What changed in the outcomes
    • EditedMetastasisProgression-free survivalSurvival (PFS)Time frame: From randomization to first evidence of metastatic disease or death from any cause, assessed up to 4 years → Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
    • EditedBladder-intact event-free survival Intact Event Free Survival (BI-EFSBIEFS)Time frame: From randomization to the first BI-EFS event, assessed up to 4 years → Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
    • Edited1-year Bladder cancer Cancer-specific survivalSurvival RateTime frame: From randomization to death from bladder cancer, assessed up to 4 years → Assessed at baseline, every 12 weeks for 1 year
    • EditedProgressionMetastasis-free survivalSurvival (MFS)Time frame: From randomization to first of local progression, nodal or distant metastasis, or death from any cause, assessed up to 4 years → Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
    • EditedDuration of Complete response durationResponseTime frame: From the date of the biopsy documenting the complete response to the time of muscle invasive recurrence, local progression, evidence of metastatic disease or death due to any cause, assessed up to 4 years → Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
    • EditedSalvage cystectomy rateCystectomy RateTime frame: Up to 4 years → Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
    • AddedTreatment-related Grade 3 or Higher Adverse Event RateTime frame: Assessed every 3 weeks while on treatment, up to 4 years
    • Added1-year Overall Survival (OS) RateTime frame: Assessed at baseline, every 12 weeks for 1 year
    • RemovedOverall survivalTime frame: From randomization to death from any cause, assessed up to 4 years
    • RemovedIncidence of adverse eventsTime frame: Up to 4 years
    • Addedother outcomeAssociations Between Clinical Outcomes and Stratification FactorsTime frame: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
    • Addedother outcomeTo Collect and Bank Tumor Tissue and Blood Specimens at Pre- and Post-treatment With chemoRT +/- Durvalumab to Determine Predictive or Prognostic Markers.Time frame: Assessed at baseline and 16 weeks
    + 4 other changes: index terms, verification date, oversight details and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04216290
Responsible party
Sponsor
First posted
Jan 2, 2020
Start date
Mar 17, 2021
Primary completion
Feb 4, 2026
Completion
May 19, 2027 (estimated)
Results posted
Nov 17, 2026
Last update
Nov 17, 2026

Study contacts

Monika Joshi
principal investigator · ECOG-ACRIN Cancer Research Group

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cisplatin · Durvalumab · Fluorouracil · Gemcitabine · Mitomycin

Start the discussion